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ABSTRACT 
Insulin resistance is a common feature of obesity and predisposes individuals to various 
prevalent pathological conditions. G protein-coupled receptor kinase 2 (GRK2) 
integrates several signal transduction pathways and is emerging as a physiologically 
relevant inhibitor of insulin signaling. GRK2 abundance is increased in humans with 
metabolic syndrome and in different murine models of insulin resistance. To support 
GRK2 as a potential drug target in type 2 diabetes and obesity, we investigated whether 
lowering GRK2 abundance reversed an ongoing systemic insulin-resistant phenotype, 
using a mouse model of tamoxifen-induced GRK2 ablation after high fat diet-dependent 
obesity and insulin resistance. Tamoxifen-triggered GRK2 deletion impeded further 
body weight gain, normalized fasting glycemia, improved glucose tolerance and was 
associated with preserved insulin sensitivity in skeletal muscle and liver, thereby 
maintaining whole body glucose homeostasis. Moreover, when continued to be fed a 
high fat diet, these animals displayed reduced fat mass and smaller adipocytes, were 
resistant to the development of liver steatosis, and showed reduced expression of pro-
inflammatory markers in the liver. Our results indicate that GRK2 acts as a hub to 
control metabolic functions in different tissues, which is key to controlling insulin 
resistance development in vivo. These data suggest that inhibiting GRK2 could reverse 
an established insulin-resistant and obese phenotype, thereby putting forward this 
enzyme as a potential therapeutic target linking glucose homeostasis and regulation of 
adiposity.   
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INTRODUCTION 
Insulin resistance is characterized by a reduced responsiveness to circulating insulin, 
and is a common feature of obesity that predisposes to several pathological conditions, 
including hyperinsulinemia, glucose intolerance, hypertension, non-alcoholic fatty liver 
disease (NAFLD), cardiovascular disease, and type 2 diabetes, and is becoming a global 
public health problem (1). A better knowledge of how different intracellular pathways 
integrate to fine-tune the response to insulin, body weight gain and metabolic rate might 
help identify novel therapeutic strategies beyond diet control, physical exercise and 
currently used pharmaceutical agents.  
G protein-coupled receptor kinase 2 (GRK2) has been widely studied for its role in the 
desensitization of G protein-coupled receptors (GPCRs) (2). GRK2 can also impact cell 
signaling networks by directly interacting with and/or phosphorylating non-GPCR 
components of transduction cascades, and thus has emerged as an integrative node of 
cellular networks (3-5). Since Anis et al. (6) have demonstrated that peptide GRK2 
inhibitors ameliorate glucose homeostasis in different animal models of diabetes, 
several reports have put forward a role for GRK2 in the regulation of insulin response 
(7, 8). GRK2 abundance is increased in blood mononuclear cells from metabolic-
syndrome patients and in different models of insulin resistance, such as human visceral 
adipocytes, and in white adipose tissue (WAT) and muscle of TNFα-, aging- or high-fat 
diet (HFD)-induced murine models, suggesting that increased GRK2 abundance may 
contribute to the development or maintenance of this condition. Moreover, enhanced 
GRK2 abundance decreases insulin sensitivity in several cell types and tissues (9). On 
the other hand, GRK2 inhibits β-adrenergic receptors (βAR) and decreased GRK2 
abundance enhances energy expenditure and thermogenesis in brown adipose tissue 
(BAT), at least partially by increasing adrenergic signaling (10). Cardiac GRK2 may 
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also participate in the cross-talk between adrenergic and insulin receptor pathways (11, 
12).  
Overall, these data suggest that GRK2 may act as a global metabolic regulator due to its 
ability to directly target both the insulin cascade and key GPCRs related to insulin 
sensitivity and metabolism. To support GRK2 as a potential drug target in type 2 
diabetes and obesity, it would be necessary to show that loss of GRK2 can revert an 
ongoing systemic insulin resistance phenotype. Apart from certain peptides and 
serotonin reuptake inhibitors that also have an effect on GRK2 (6, 13, 14), specific 
GRK2 inhibition must be achieved by indirect genetic means.  Thus, we used a 
tamoxifen (Tam)-inducible GRK2 deletion mouse model, which allowed us to ablate 
GRK2 after HFD-induced obesity and insulin resistance developed, which would mimic 
some aspects of the effects of a putative GRK2 inhibitory drug. We show that 
decreasing GRK2 abundance reversed key systemic and tissue-specific aspects of an 
established insulin-resistant and obese phenotype, thus revealing that targeting GRK2 
may allow for the multi-tissue treatment of metabolic disorders related to obesity. 
 
RESULTS 
Tamoxifen-induced GRK2 deletion during a HFD prevents further body weight 
gain and restores glucose tolerance and global insulin sensitivity. 
Cre-/-GRK2fl/fl animals (Tam-GRK2+/+), used as controls, and Cre+/-GRK2fl/fl mice, that 
undergo GRK2 deletion upon tamoxifen treatment (Tam-GRK2-/- animals), were fed 
either a standard diet (SD) or transferred to a HFD for 8 weeks (Suppl. Fig. 1A). At this 
point we evaluated the increase in body weight, fasting glucose concentrations and the 
onset of systemic insulin resistance in the animals fed a HFD compared with their SD-
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fed littermates (Suppl. Fig.1B-D). Once diet-induced insulin resistance and obesity were 
confirmed in both genotypes, mice were injected with tamoxifen and maintained for 5 
more weeks on a HFD. Tamoxifen injection markedly decreased GRK2 protein 
abundance in several tissues in Tam-GRK2-/- mice (Suppl. Fig. 1E). The extent of 
GRK2 loss ranged from 60 to 80% depending on the organ, consistent with the reported 
variability in the extent of Cre-mediated recombination in different tissues (15) and with 
published work (16). Body weight did not differ between the two groups during the 8 
weeks of HFD prior to tamoxifen injection (Figure 1A). As reported (17), the 
administration of tamoxifen for 5 days caused a transient decrease in body weight in 
both groups of mice. However, control mice (Tam-GRK2+/+) continued to gain weight 
after tamoxifen injection throughout the five additional weeks of HFD, whereas further 
body weight gain was prevented in Tam-GRK2-/- mice (Figure 1A and Suppl. Fig. 2) 
relative to both control Tam-GRK2+/+ animals and also to Cre+/- mice without floxed 
GRK2 alleles (Tam-Cre+/-) (Suppl. Fig. 3A). We cannot rule out that control and Tam-
GRK2-/- animals present a differential sensitivity to tamoxifen treatment, which might 
influence subsequent body weight gain. However, the initial decrease in body weight 
upon tamoxifen injection was similar in both mouse genotypes (Figure 1A), suggesting 
that tamoxifen treatment per se does not have a major impact on the differences in body 
weight observed along the following weeks. Food intake did not differ between 
genotypes (Figure 1B).   
Tam-GRK2+/+ mice showed a significant deterioration in glucose tolerance at the end of 
the experimental protocol (13 weeks of HFD), indicating a progressive intensification of 
insulin resistance during the 5 additional weeks of HFD feeding. In contrast, Tam-
GRK2-/- mice showed improved glucose homeostasis (Figure 1C-D) suggesting that the 
previously observed glucose intolerance was reversed. Accordingly, the area under the 
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curve showed a significant enhancement of glucose tolerance in Tam-GRK2-/- mice at 
the end of the HFD feeding period (Figure 1E).  
Consistent with the glucose tolerance tests, control Tam-GRK2+/+ mice displayed 
decreased insulin sensitivity throughout the progression of the HFD (Figure 1F), 
whereas Tam-GRK2-/- mice showed significantly enhanced insulin sensitivity at the end 
of the HFD after Tam-induced GRK2 deletion compared to before tamoxifen 
administration or to control littermates (Figure 1G-H), indicating that the improved 
glucose homeostasis in Tam-GRK2-/- mice could be attributed to enhanced global 
insulin sensitivity. In addition, GRK2 deletion after 8 weeks of HFD reduced fasting 
glucose plasma concentrations in the face of high fat feeding, without increasing 
insulinemia (Figure 1I-J), indicating that Tam-GRK2-/- mice	  were protected against the 
hyperglycemia and hyperinsulinemia characteristic of insulin-resistant and pre-diabetic 
states. These results demonstrated that GRK2 depletion during diet-induced obesity and 
insulin resistance resulted in improved whole-body glucose homeostasis and enhanced 
insulin sensitivity.  
 
GRK2 depletion enhances insulin-induced phosphorylation of AKT in peripheral 
tissues 
Skeletal muscle is the major site for insulin-induced glucose disposal and a decreased 
insulin response in this tissue is the initiating defect in insulin-resistant states	  during the 
development of type 2 diabetes (18). Consistent with the increased glucose tolerance 
and enhanced insulin sensitivity in Tam-GRK2-/- mice, GRK2 ablation restored insulin-
induced phosphorylation of AKT at Ser473 in muscle (Figure 2A). Moreover, insulin-
induced AKT phosphorylation was also enhanced in Tam-GRK2-/- mice in other tissues 
that are key for metabolic regulation, such as epididymal WAT (eWAT) and liver 
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(Figures 2B-C), although the increase was not statistically significant in eWAT. Insulin-
induced phosphorylation of AKT was similar in post-tamoxifen Cre+/- mice (Tam-Cre+/-
) and Cre-/- animals (Tam-Cre-/-, used as controls) (Suppl. Fig. 3B), thus discarding non-
specific effects due to Tam-induced Cre nuclear translocation in the analyzed tissues. 
Control Tam-GRK2+/+ and Tam-GRK2-/- mice did not differ in the abundance of 
inhibitors of insulin signaling (PTP1B and PTEN) or of key insulin transduction 
partners (p110β, p85β, IRS1 or IRS2) (Suppl. Fig. 4) that could explain the insulin-
sensitizing effect of low GRK2 abundance. Overall, these data indicate that GRK2 
depletion in Tam-treated mice plays a relevant role in the preservation of insulin 
sensitivity in the analyzed tissues, probably through already described mechanisms (9), 
and that this insulin sensitization can explain the improved glucose homeostasis caused 
by reducing GRK2 abundance during a HFD. 
 
Inducible loss of GRK2 is associated with reduced epidydimal fat pad weight. 
Epididymal fat pad weight was reduced in HFD-fed Tam-GRK2-/- mice compared to 
HFD-fed control mice (Figure 3A). Histological analysis revealed a significantly greater 
frequency of small adipocytes and a lower frequency of mid-sized and large adipocytes 
in eWAT from these mice (Figure 3B). Tam-GRK2-/- mice displayed no differences in 
the abundance of C/EBPα, a transcription factor that promotes preadipocyte 
differentiation, or PPARγ, another transcription factor that is key for adipogenesis (19) 
(Figure 3C), suggesting that impaired differentiation did not cause the decrease in 
adipocyte size. Moreover, the increase in both protein abundance and gene expression 
of hormone-sensitive lipase (HSL), a critical enzyme for cAMP-dependent lipolysis 
(20) (Figure 3D) in Tam-GRK2-/- mice suggested that the decrease in fat mass was due 
to enhanced lipolysis in eWAT. Indeed, the eWAT depot from Tam-GRK2-/- mice 
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showed an enhanced ex vivo response to the β-adrenergic agonist isoproterenol (Figure 
3E) and HFD-fed Tam-GRK2-/- mice had a 30% increase in circulating free fatty acids 
(FFAs) in the fasted but not in the fed state (Figure 3F). These results indicate a blunted 
lipolytic response to fasting in HFD-fed control mice that was absent in Tam-GRK2-/- 
mice. 
 
GRK2 ablation increases the expression of thermogenic and fatty acid oxidation 
markers in brown adipose tissue 
By contributing to whole-body fatty acid oxidation and energy expenditure, BAT 
regulates fat content (21, 22). The BAT of HFD-fed Tam-GRK2-/- mice showed an 
increased number of smaller adipocytes, which was associated with a higher proportion 
of multilocular lipid droplets (Figure 4A) suggesting that GRK2 ablation might increase 
BAT function. The BAT from Tam-GRK2-/- animals showed an increase both in protein 
and mRNA abundance of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting 
enzyme that controls fatty acid entry and oxidation in the mitochondria (23) (Figure 4B-
C), as well as augmented protein abundance of uncoupling protein 1 (UCP1), which is 
involved in thermogenesis [reviewed in (22, 24)]. These effects could underlie an 
increased capacity for fatty acid metabolism and thermogenesis in the BAT of these 
mice. However, the expression of the mRNAs encoding UCP1 or of its transcriptional 
activators PPARγ coactivator 1α (PGC1α) (22, 25) or type 2 deiodinase (Dio2) (25), 
which locally produces T3 required for the adrenergic induction of UCP1 (26) , suggest 
a post-transcriptional mechanism controlling UCP1 abundance in these mice (Fig. 4C). 
In brown adipocytes, lipolysis is essential to activate thermogenesis, because it allows 
the release of fatty acids, which activate UCP1 (24, 27). In line with our observations in 
WAT, mRNA abundance of the HSL gene (lipe) was significantly increased in BAT 
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upon GRK2 deletion (Figure 4C), as was the ex vivo lipolytic response of BAT explants 
from these mice to the β-adrenergic agonist isoproterenol (Figure 4D). These data point 
to an increased capacity for fatty acid metabolism in Tam-GRK2-/- mice and might 
explain the absence of lipotoxicity observed in these animals despite the increased 
plasma free fatty acid availability.  
The increased response of adipose tissues after GRK2 deletion to adrenergic input, a 
key pathway by which the sympathetic nervous system (SNS) modulates energy 
homeostasis (24, 25, 27), raised the issue of whether this effect was also responsible for 
the overall glucose homeostasis phenotype of Tam-GRK2-/- animals. To answer this 
question, glucose tolerance tests were performed in control or GRK2-deleted mice 
treated with the β-adrenergic antagonist propranolol to abrogate adrenergic input. 
Propranolol resulted in impaired glucose handling in HFD-fed control mice but not in 
GRK2-depleted mice (Figure 4E). These data suggest that the improvement in glucose 
tolerance obtained upon GRK2 depletion prevails even under conditions of adrenergic 
blockade, and demonstrates that GRK2 loss can influence insulin sensitization 
independently of its effects on the control of adrenergic stimulation.  
 
GRK2 deletion during HFD feeding protects against the development of NAFLD 
and decreases the expression of pro-inflammatory markers in the liver.  
Chronic exposure of mice to HFD induces lipid accumulation in this tissue, leading to 
NAFLD. Histological analysis revealed marked steatosis in livers of HFD-fed control 
mice. In contrast, the degree of fat accumulation in the liver was substantially alleviated 
in HFD-fed Tam-GRK2-/- mice compared to control animals (Figure 5A). Liver weight 
was also significantly lower after 13 weeks of HFD in Tam-GRK2-/- mice compared to 
controls (Figure 5B). These effects are consistent with the decreased hepatic lipid 
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accumulation, and unrelated to the presence of Cre (Suppl. Fig. 5). The abundance of 
lipogenic enzyme fatty acid synthase (FAS) and the transcription factor PPAR is 
increased in fatty liver (28, 29); however, Tam-GRK2-/- mice did not show differences 
in the mRNA expression for the fatty acid entry and oxidation marker Cpt1a and 
reduced mRNA and protein abundance for FAS and PPAR (Figure 5C-D), suggesting 
decreased lipogenesis.  
The inflammatory activation of macrophages and Kupffer cells has been implicated in 
both obesity-induced insulin resistance and fatty liver disease in parallel with the 
activation of stress- and inflammation-related kinases (30). Immunostaining and mRNA 
expression for F4/80, a representative macrophage and Kupffer cell marker, were 
comparable between HFD-fed control and Tam-GRK2-/- mice (Figure 5 E-G). However, 
in HFD-fed control animals, macrophages frequently aggregated to surround 
hepatocytes with large intracellular lipid droplets (arrows in Figure 5E), which is 
reminiscent of hepatic-crown like structures observed in adipose tissue from obese 
animals and humans and considered to be an indicator of the presence of pro-
inflammatory macrophages (24) (31). Notably, HFD-fed Tam-GRK2-/- mice showed a 
scattered macrophage distribution, with lower numbers of hepatic crown-like structures 
(Suppl. Fig. 6A). Consistently, the expression of mRNAs characteristic of the pro-
inflammatory M1 macrophage phenotype, such as those encoding the inducible nitric 
oxide synthase (iNOS), as well as the phosphorylation of JNK, a kinase that is involved 
in inflammation (32), was decreased in Tam-GRK2-/- mice (Suppl. Fig. 6B-C) . In 
addition, the ratio of M2 (anti-inflammatory, Mannose Receptor	  1 (mrc1)-expressing) to 
M1 macrophages (pro-inflammatory, (inducible nitric oxide synthase (nos2)-
expressing) was significantly increased in Tam-GRK2-/- mice (Figure 5H), in 
accordance with a tendency towards a reduced expression of tumor necrosis factor-
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alpha-encoding mRNA (tnfa) in these mice, indicating that lowering GRK2 abundance 
decreases HFD-induced hepatic steatosis and inflammation.  
 
DISCUSSION 
In this work, we provide evidence that global decrease of GRK2 abundance reversed 
key systemic and tissue features of an already established insulin-resistant and obese 
phenotype in HFD-fed mice. Tamoxifen-induced GRK2 deletion reduced further body 
weight gain despite continued HFD feeding, normalized glucose intolerance, led to 
improved insulin sensitivity, and prevented the development of adiposity and fatty liver. 
These data, together with the increase in GRK2 abundance in liver, muscle and WAT in 
murine insulin resistance experimental models (9) suggest that the ability of GRK2 to 
control metabolic functions in different tissues is key to the development of insulin 
resistance in vivo. We show here that at least four potentially tissue-specific processes 
appear to be involved in the physiological effects of GRK2 reduction in HFD-fed mice: 
improved insulin signaling in peripheral tissues, enhanced lipolysis in WAT and BAT, 
increased expression of mRNAs encoding proteins involved in fatty acid oxidation and 
thermogenesis in BAT, and reduced steatosis and inﬂammation in the liver. We 
postulate that such pleiotropic effects of GRK2 abundance are due to the ability of 
GRK2 to directly modulate both the insulin receptor cascade and key GPCRs that 
control adiposity and metabolic rate such as β-adrenergic receptors. 
The glucose-lowering effect of decreasing GRK2 abundance appeared to involve 
preserved peripheral insulin sensitivity, because insulin-targeted tissues key for glucose 
homeostasis exhibited augmented insulin-induced AKT phosphorylation. In addition to 
these tissue-autonomous effects, part of the enhanced insulin sensitivity of Tam-GRK2-/- 
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mice could be related to their reduced adiposity, decreased fat mass accretion and 
adipocyte size, and increased lipolysis and enhanced response to adrenergic input in 
mature WAT adipocytes. However, the potential impact of increased lipolytic flux in 
the global insulin-resistant phenotype is not straightforward, because a high lipolytic 
rate can be associated with insulin resistance (33). Conversely, impaired lipolytic 
capacity has been postulated to result in an improved overall metabolic status, because 
reduced release of free fatty acids from adipose stores would protect peripheral tissues 
from lipotoxicity (34, 35). However, some animal models of impaired lipolysis display 
an overall impairment in systemic metabolic function (36). This finding supports the 
notion that a decreased release of free fatty acids per se does not necessarily predict an 
improvement of systemic insulin sensitivity,	   because the deficiency in free fatty acid 
mobilization as a consequence of reduced WAT metabolic flexibility may cause 
systemic metabolic dysfunction.	   Accordingly, despite their enhanced lipolytic 
phenotype, Tam-GRK2-/- mice did not display signs of lipotoxicity, but rather increased 
insulin sensitivity. We hypothesize that this apparent paradox could be explained by the 
improved function of BAT observed upon GRK2 loss, as indicated by the preserved 
morphology of this tissue and its enhanced adrenergic-induced lipolytic capacity, as 
well as the increased expression of thermogenic (UCP1) and FA oxidation (CPT1) 
markers. These changes could allow BAT to act as an efficient "metabolic sink" for the 
extra free fatty acids produced in WAT (Fig. 6) and might explain the lack of 
lipotoxicity in Tam-GRK2-/- animals despite the increased plasma free fatty acid 
concentrations. This explanation is consistent with the increased energy expenditure and 
enhanced BAT fatty acid oxidation and thermogenic capacity previously reported in 
GRK2+/- mice (10). The finding that GRK2-depleted animals maintained glucose 
homeostasis upon propranolol treatment indicates that increased β-adrenergic signaling 
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is not fully responsible for the improvement in glucose tolerance, and that GRK2 loss 
can influence insulin sensitization independently of its effects on the control of 
adrenergic stimulation. However, increased adrenergic signaling in these mice could 
account for other aspects of their phenotype, such as the increased lipolytic capacity and 
the protection against diet-induced weight gain.  
The liver is another key organ for metabolic regulation, and we demonstrated here that 
decreasing GRK2 abundance protected against HFD-induced hepatic insulin resistance 
and impaired lipid accumulation, an effect that was associated with reduced expression 
of the genes encoding FAS and PPARγ, which are increased in fatty liver (29, 37). On 
the other hand, insulin resistance is increased by the accumulation of macrophages that 
secrete proinflammatory mediators and by macrophage polarization from an alternative 
anti-inflammatory M2 activation state to a pro-inflammatory M1 activation state (38). 
In control HFD-fed mice, macrophages displayed an M1-like pro-inflammatory profile, 
and were predominantly found surrounding hepatocytes with large lipid droplets in 
hepatic crown-like structures, which are involved in disease progression from simple 
steatosis to non-alcoholic steatohepatitis (39). In contrast, livers from HFD-fed Tam-
GRK2-/- mice had lower activation of inflammatory pathways such as JNK, a scattered 
distribution of macrophages, and an increased M2 to M1 ratio. Hepatic macrophages 
display remarkable plasticity in their activation programs (38) ranging from the 
activation of macrophages triggered by steatosis in NAFLD, to the beneficial role in 
metabolic syndrome and type 2 diabetes played by M2 or alternatively activated 
macrophages (40). The reduced hepatocyte fat deposition upon GRK2 deletion may 
have helped suppress tissue inflammation by preventing either the recruitment or pro-
inflammatory activation of macrophages (or both processes). Nevertheless, decreasing 
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GRK2 abundance in macrophages themselves may also have a direct effect on the 
polarization or migration of these cells, a possibility that we are currently studying. 	  
Overall, we suggest that GRK2, by directly inhibiting the insulin receptor cascade and 
controlling adrenergic receptor signaling, can regulate body weight gain, adiposity, 
metabolic rate and downstream targets of the insulin pathway in multiple tissues. Under 
pathological conditions, concurrent increases in GRK2 abundance in several tissues (9) 
would favor the development of an insulin-resistant phenotype, whereas decreasing 
GRK2 abundance could orchestrate a multi-organ anti-obesity response that collectively 
would reverse both systemic and tissue-specific features of such insulin-resistant and 
obese phenotype (Figure 6). Although we investigated here the impact of GRK2 
deletion in WAT, BAT and liver, we cannot rule out additional effects of global GRK2 
loss in other organs that could influence the observed phenotype, such as gut hormone 
production or sensitivity, sodium excretion, insulin synthesis, central effects, 
catecholamine concentrations and others. 
At the molecular level, enhanced GRK2 abundance impairs insulin-mediated AKT 
stimulation and glucose uptake by interacting with IRS1 in adipocytes and myocytes 
(9), by directly phosphorylating IRS1 at Ser307 in cardiomyocytes (41), or by mediating 
insulin resistance induced by endothelin-1 by inhibiting both Gαq/11 and IRS1 
pathways in 3T3-L1 adipocytes (42). Because HFD increases GRK2 abundance in 
WAT, muscle and liver (9), this inhibition of insulin signaling by GRK2 would be 
precluded in these key tissues with an efficient decrease in the amount of this kinase 
such as that observed in Tam-GRK2-/- mice.  
Additional effects observed upon GRK2 deletion could be ascribed to increased 
adrenergic signaling related to the canonical function of GRK2 in βAR phosphorylation 
and desensitization. βARs are the main activators of the lipolytic process in WAT (43). 
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Transgenic mice overexpressing β1ARs have decreased adipose stores as a result of 
increased lipolytic activity and are resistant to becoming obese (44). Hence, the 
increased lipolysis in the WAT of Tam-GRK2-/- mice would be consistent with 
enhanced activation of adrenergic cascades upon GRK2 deletion, which would help 
correct the defective lipid mobilization and metabolism characteristic of obesity (45). 
However, a decompensated stimulation of the adrenergic axis can also have detrimental 
effects, because a long-term increase in circulating plasma concentrations of free fatty 
acids can indirectly stimulate de novo glucose synthesis, and β2AR activation induces 
glycogenolysis and gluconeogenesis which may further exacerbate hepatic and skeletal 
muscle-based insulin resistance. Moreover, persistent sympathoadrenal activation is 
linked to glucose dysregulation and insulin resistance (46). Because insulin resistance 
did not occur upon GRK2 deletion, other compensatory mechanisms and tissue-specific 
effects must also be taking place.  
One such compensatory mechanism could be increased BAT function. Sympathetic 
stimulation is critical for key effects of BAT on energy homeostasis including 
thermogenesis (47) and glucose utilization (48).	  Moreover, activation and/or increased 
abundance of UCP1 may ameliorate impaired glucose metabolism caused by insulin 
resistance (49). Furthermore, whereas sympathetic over-activity might be associated 
with obesity (50), catecholamine sensitivity is decreased in the BAT of obese organisms 
(51). Therefore, enhanced adrenergic signaling in BAT upon decreasing GRK2 
abundance, leading to increased CPT1 and UCP1, would not only promote enhanced 
fatty acid oxidation (which would help to prevent lipotoxicity caused by increased 
release of free fatty acids by WAT; Figure 6), but also contribute to the improved 
glucose homeostasis in Tam-GRK2-/- mice. Our data suggest that UCP1 abundance was 
increased by a post-transcriptional mechanism in the BAT of Tam-GRK2-/- mice. 
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Because enhanced adrenergic activation, insulin and fatty acids inhibit proteolysis in 
BAT (52, 53), either enhanced insulin sensitivity or increased lipolytic capacity could 
be responsible for a reduced turnover rate of UCP1 in these mice. Because the main 
receptor subtype that mediates catecholamine-stimulated thermogenesis (24) and 
glucose uptake (54)	   in brown adipocytes is the β3AR, which is resistant to agonist-
induced desensitization and/or down-regulation (55), altered GRK2 abundance may 
impact BAT adrenergic pathways through alternative mechanisms downstream and/or 
independent from β3AR that deserve further investigation.  
Our present findings suggest that GRK2 may be a potential target for therapeutic 
intervention for metabolic syndrome. GRK2 has also been implicated in the modulation 
of insulin response in cardiac dysfunction (56) and hypertension (57, 58). Our 
experimental approach in decreasing GRK2 abundance in several tissues would mimic 
some aspects of the use of selective and effective GRK2 inhibitor, although the absence 
of the protein cannot fully recapitulate pharmacological inhibition. Accordingly, GRK2 
peptide inhibitors improve parameters related to glucose homeostasis in animal models 
of diabetes (6), and exercise, which has a beneficial role in type 2 diabetes, reduces 
GRK2 abundance (59). It is tempting to suggest that selective peptide or small molecule 
inhibitors of GRK2 such as those being developed based on the crystal structures of this 
kinase (14, 60) could be used in the near future to further characterize the proof of 
concept results obtained in genetically-modified animal models, and that GRK2 
inhibitors may hold great promise for the treatment of type 2 diabetes.  
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MATERIALS AND METHODS 
Tam-GRK2-/- Mice  
Floxed homozygous GRK2 mice (GRK2fl/fl) (61) and transgenic mice overexpressing a 
Cre recombinase fused to a mutant form of the estrogen receptor (ER) to allow for 
tamoxifen-dependent activation [B6.Cg-Tg(CAGCre/Esr1* 5Amc/J] (62), were 
obtained from the Jackson Laboratories. Cre+/-GRK2fl/- offsprings were backcrossed 
with GRK2fl/fl mice to obtain mice carrying both floxed GRK2 alleles and either none 
(Cre-/-GRK2fl/fl) or a single CreER allele (Cre+/-GRK2fl/fl). Recombination was induced 
by an intraperitoneal injection of tamoxifen (Tam) (Sigma-Aldrich, 2 mg/mouse, in 
saline containing 9% ethanol and 51% sunflower oil) for 5 consecutive days. Animals 
were genotyped by PCR on genomic DNA using reported oligonucleotides (61). 
Animal Protocols  
Mice were housed on a 12-hour light/dark cycle with free access to food and water in 
the animal facility of the University of Utrecht (the Netherlands). At 8 weeks of age, 
mice continued on a standard diet (SD) (2018S Harlan-Teklad, 12% calories from fat) 
or were fed a HFD (Sniff E15126-34, 52% calories from fat) during 8 weeks. At this 
time point, glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) were 
performed. HFD-fed mice were then injected with tamoxifen (Tam) and maintained on 
the HFD for 5 more weeks. Body weight and food intake were measured weekly. At the 
end of the HFD, GTT and ITT were repeated. For β-adrenergic blockade, mice were 
injected with propranolol (Sigma-Aldrich, 5mg/Kg body weight) one hour prior 
performing the GTT. Before sacrifice, mice were intraperitoneally injected with either 
vehicle (NaCl 0.9%) or insulin (Actrapid®, Novo Nordisk, 1 IU/Kg body weight). After 
10 minutes, mice were euthanized, tissues were surgically removed, immediately 
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weighted and either fixed or frozen in liquid nitrogen to be stored at -80°C. All 
experiments were performed in accordance with international guidelines and approved 
by the University Medical Center Utrecht and UAM experimental animal committee.  
Metabolic assays 
GTTs and ITTs were performed as previously described (9). Glucose (2g/Kg body 
weight) and insulin (0.8 U/kg body weight) were administered intraperitoneally. 
Glucose concentration was determined in tail blood samples using an automatic 
analyzer (One Touch Ultra), from Life Scan.  
Plasma insulin concentration was measured by ELISA (Mercodia), and released non-
esterified fatty acids (NEFA) was measured with an enzymatic method (NEFA-HR kit 
Wako Chemicals). 
Adipocyte Size Determination  
Adipose tissue sections were stained with haematoxylin and eosin for the evaluation of 
adipocyte size. Individual adipocyte areas within each field were determined using 
image analysis software (ImageJ). Relative adipocyte size was calculated in arbitrary 
fields by quantitation of 150 cells in at least four different randomly chosen fields per 
mouse.  
Ex vivo lipolysis 
Epididymal white and brown fat pads were isolated from 12h-fasted mice and sliced 
into equal-sized pieces of ∼50 mg and ∼20 mg respectively. Explants were washed 
twice in PBS and stimulated with isoproterenol (10 µM, Sigma-Aldrich) for 2h at 37°C 
in 0.5 ml of DMEM supplemented with 1% FA-free BSA. NEFA release was measured 
following manufacturer´s indications (NEFA-HR kit Wako Chemicals) in aliquots from 
incubation media at 0 and 120 min, and was normalized relative to tissue weight.   
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Immunohistochemical detection of the F4/80 macrophage marker and 
quantification of hepatic “crown-like structures” (hCLS).  
Liver tissue sections were de-paraffinized and rehydrated, and slides were incubated 
overnight with the primary antibody anti-F4/80 (clone BM8, Abcam) to perform 
immunohistochemical detection as previously described (63, 64). The absence of the 
primary antibody was used as negative control. The presence of macrophages (F4/80 
staining positive area) was determined using image analysis software (ImageJ). Three to 
five different high-power fields from each section were analyzed per animal. The 
number of hCLS in the whole area of each F4/80-stained section was quantified and 
expressed as the mean number/mm2. 
Western Blot analysis 
Tissues were homogenized using metal beads in a Tissue Lyser as previously described 
(65). 30-50 µg of total protein was resolved per lane by SDS-PAGE and transferred to a 
nitrocellulose membrane. Blots were probed with specific antibodies against 
phosphorylated (Ser473) and total AKT, phosphorylated (Thr183/Tyr185) and total JNK1/2 
(Cell Signalling), C/EBPα, PPARγ, GRK2 (Santa Cruz), HSL and GAPDH (Abcam) as 
previously described (63). Equal amounts of protein as determined by the DC protein 
assay method (Bio-Rad) were loaded per lane. Equivalent loading was further assessed 
by Ponceau staining and GAPDH abundance. Immunoreactive bands were visualized 
using enhanced chemiluminescence (ECL; Amersham Biosciences) or the Odissey 
Infrared Imaging System (Li-Cor Biosciences). Films were scanned with a GS-700 
Imaging Densitometer and analyzed with Quantity One Software (Bio-Rad), or using an 
Odissey Classic reader and the Odissey software package 3.0 (Li-Cor Biosciences). 
mRNA isolation and Real Time PCR 
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RNA was extracted using metal beads in a Tissue Lyser and the RNeasy Mini Kit 
(Qiagen) following the instructions provided by the supplier. Quantity and quality of 
RNA were analyzed using Nanodrop ND-1000 (Thermo Scientific).  
RT-PCRs were performed in the Genomic Facility at CBMSO using Light Cycler 
equipment (Roche) and primers labeled with Syber Green (Supplementary Table 1) 
(Sigma). 
A geometric mean of three stably expressed and commonly used reference genes 
(ywhaz, gapdh and 18s) was used for data normalization in the liver and a geometric 
mean of two (ppia and b2m) was used for data normalization in WAT and BAT. qPCRs 
and statistical analysis of the data were performed using GenEx software.  
Data analysis  
All data are expressed as mean values ± SEM and n represents the number of animals. 
Normal distribution was determined using a Shapiro-Wilk normality test prior to 
statistical analysis. Whenever normality test was positive, statistical significance was 
analyzed by using unpaired Student’s t test or one- or two-way repeated measures 
ANOVA followed by Bonferroni’s post hoc test. When the normality test was not 
positive, or when significant differences were found between variances (determined by 
Bartletts´or by  F-test of equality of variances), statistical significance was analyzed 
using Mann-Whitney test,  unpaired t test with Welch's correction or Kruskal Wallis 
followed by Dunn's Multiple Comparison Test. Differences were considered statistically 
significant when P value <0.05. 
 
SUPPLEMENTARY MATERIALS 
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Supplementary Figure 1.  Characterization of an obese and insulin-resistant phenotype 
after eight weeks of HFD, before tamoxifen treatment, and quantification of tamoxifen-
induced GRK2 depletion. 
Supplementary Figure 2. HFD-induced weight gain in control mice compared with 
Standard Diet (SD)-fed mice. 
Supplementary Figure 3. CreER expression or translocation to the nucleus does not 
affect body weight gain or insulin-induced phosphorylation of AKT in muscle, eWAT, 
or liver. 
Supplementary Figure 4.  The abundance of components in or inhibitors of the insulin 
signaling pathway is not changed upon GRK2 loss in muscle or liver.  
Supplementary Figure 5.  CreER expression or translocation to the nucleus does not 
affect lipid accumulation in the liver. 
Supplementary Figure 6. Decreased abundance of inflammation markers in the liver 
upon tamoxifen-induced GRK2 loss. 
Supplementary Table 1. Primers used for real-time PCR analysis. 
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FIGURE LEGENDS 
Figure 1. Tamoxifen-induced GRK2 ablation prevents diet-induced obesity and 
reverses HFD-induced glucose intolerance. Mice were fed a HFD for 8 weeks, 
injected with tamoxifen and maintained for 5 more weeks on the HFD. (A) Body weight 
evolution (expressed in g) along the 13 weeks of high fat feeding. (B) Daily food intake: 
no significant differences were found between any pair of conditions. (C and D) 
Intraperitoneal glucose tolerance tests (GTTs) were performed either at 8 weeks of HFD 
(before tamoxifen administration, dotted lines) or 5 weeks after tamoxifen injection, 
following a total of 13 weeks of HFD (solid lines) in control (Cre-/-GRK2fl/fl) mice (C, 
black), and Cre+/-GRK2fl/fl mice (D panel, red). (E) Histogram showing the GTT area 
under the curve (AUC) of data in (C) and (D). (F and G) Insulin tolerance tests (ITTs) 
were performed in mice described in (C) and (D), before and after tamoxifen treatment. 
(H) Histogram showing the ITT area under the curve of data in (F) and (G). (I and J) 
Serum concentrations of fasting glucose (I) and insulin (J) from HFD-fed control (Cre-/-
GRK2fl/fl) and Tam-GRK2-/- mice. Results in (A) to (J) are means ± SEM of 7-8 mice 
per group. Statistical analysis was performed by two-way repeated measures ANOVA 
followed by Bonferroni’s post hoc test (A-H) or by unpaired two-tailed t test (I-J). *P < 
0.05; **P < 0.01. Open symbols, dotted lines = Pre-Tam; filled symbols, solid lines = 
Post-Tam; Black = Cre-/-GRK2fl/fl; Red = Cre+/-GRK2fl/fl) 
Figure 2. GRK2 loss during a HFD enhances insulin signalling in insulin-sensitive 
tissues. (A) to (C)Following the 13 weeks of HFD control and Tam-GRK2-/- mice	  were 
treated with either vehicle or insulin and tissue lysates from muscle (A), eWAT (B) and 
liver (C) were subjected to Western blot and probed with antibodies against GRK2, 
total and phosphorylated AKT (Ser473), and GAPDH. Representative immunoblots and 
densitometric analysis of four mice per group are shown. Results are expressed as % of 
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stimulation over vehicle-treated mice (basal). Results are means ± SEM of 7-8 mice per 
genotype, 3-4 mice per treatment. Statistical significance was analyzed by unpaired 
two-tailed t test (A) and (C) or by Mann-Whitney test (B). *P < 0.05. 
Figure 3. Tamoxifen-induced GRK2 depletion reduces epidydimal adipose mass 
and adipocyte size and increases markers of lipolysis. (A) eWAT weight in control 
(Tam-GRK2+/+) and Tam-GRK2-/- mice at the end of the 13-week HFD. (B) Sections of 
epididymal fat pads from control and Tam-GRK2-/- mice stained with hematoxylin and 
eosin (magnification ×10; scale bar 50 µm). Representative photomicrographs are 
shown. Relative adipocyte size was calculated by determining individual adipocyte 
areas using image analysis software (ImageJ) in at least four different randomly chosen 
fields per mouse, in 5 mice per genotype. (C) eWAT lysates were immunoblotted for 
PPARγ, C/EBPα, and FAS using GAPDH as a loading control. Representative 
immunoblots and densitometric analysis are shown. D) eWAT lysates were 
immunoblotted for HSL and subjected to real-time quantitative polymerase chain 
reaction (qPCR) to measure the expression of HSL (lipe). qPCR results were 
normalized against ppia and b2m mRNAs. Data are represented as means ± SEM of 7-8 
mice per genotype for (B) and (C) and 6 mice per genotype for (D). Statistical 
significance was analyzed by unpaired two-tailed t test. *P < 0.05;  **P < 0.01; 
***P<0.005. (E) Non-esterified fatty acid (NEFA) release from eWAT explants isolated 
from control or Tam-GRK2-/- mice (N=4-6 per genotype) was measured in supernatants 
at the indicated times of  isoproterenol stimulation. (F) Circulating non-esterified fatty 
acid serum concentrations in 13-week HFD-fed controls and Tam-GRK2-/- mice either 
fed or fasted for 16 hours. Data are represented as means ± SEM of 4-5 mice per group. 
Statistical significance was analyzed by 2-way ANOVA followed by Bonferroni post-
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hoc test (E) and by Kruskal Wallis followed by Dunn's Multiple Comparison Test (F) 
**P < 0.01.*P < 0.05;  **P < 0.01.  
Figure 4.  Decreasing GRK2 abundance during a HFD prevents fat accumulation 
within BAT and augments the expression of fatty acid oxidation and thermogenic 
markers. (A) Sections of BAT from control (Tam-GRK2+/+) and Tam-GRK2-/- mice 
after 13 weeks of HFD were stained with hematoxylin and eosin (scale bar 50 µm). 
Representative photomicrographs from 5 mice per genotype are shown. (B) BAT 
lysates were immunoblotted for GRK2, CPT1, UCP1 and GAPDH. Representative 
immunoblots and densitometric analysis are shown. (C) qPCR was used to measure the 
expression of  HSL (lipe), CPT1 (cpt1b), UCP1 (ucp1), PGC1α (ppargc1a) and Dio2 
(dio2) mRNAs. Results were normalized against ppia and b2m mRNAs. Data are means 
± SEM of 7-8 mice per genotype for (B) and 6 mice per genotype for (C). Statistical 
significance was analyzed by unpaired two tailed t test. *P < 0.05. (D) NEFA release 
from interscapular BAT explants isolated from control or Tam-GRK2-/- mice (N=4-6 
mice per genotype) was measured in supernatants at the indicated times after 
isoproterenol stimulation. Statistical significance was analyzed by 2-way ANOVA 
followed by Bonferroni post-hoc test **P < 0.01. (E) Intraperitoneal glucose tolerance 
tests (GTTs) were performed in mice treated or not with propranolol before the GTTs. 
Histogram shows the GTT area under the curve (AUC). Results are means ± SEM of 4-
6 mice per group. Statistical analysis was performed by two-way repeated measures 
ANOVA followed by Bonferroni’s post hoc test. *P < 0.05. Open symbols, dotted lines 
= Propranolol-treated; filled symbols, solid lines = No treatment; Black = Tam-
GRK2+/+; Red = Tam-GRK2-/-) 
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Figure 5.  Tamoxifen-induced GRK2 loss protects against the development of 
NAFLD and associated inflammation in the liver. (A) Liver sections from HFD-fed 
control (Cre-/-GRK2fl/fl) and Tam-GRK2-/- mice were stained with hematoxylin and 
eosin (scale bar 50 µm). Images are representative of 4-5 mice per genotype. (B) Liver 
weight in control and Tam-GRK2-/- mice. (C) Representative immunoblots and 
densitometric analysis are shown for FAS, PPARγ and GAPDH. (D) qPCR was used to 
measure the expression of mRNAs encoding PPARγ (pparg), FAS (fasn) and CPT1 
(cpt1a). Results were normalized against ywhaz  and gapdh mRNAs. Data in (B), (C), 
and (E) are means ± SEM of 7-8 mice per genotype. (E and F) Immunohistochemical 
analysis of liver sections stained with F4/80 antibody and counterstained with 
hematoxylin. Representative photomicrographs are shown and characteristic 
macrophage arrangements known as hepatic crown-like structures (hCLS) are indicated 
by arrows (E). Positively stained area was quantified using Image J Software in at least 
four different randomly chosen fields per mouse, in 4-5 mice per genotype (F). (G and 
H) qPCR was used to measure the hepatic expression of the F4/80-encoding mRNA (G) 
and the ratio between mRNAs encoding mannose receptor C type 1 (mrc1), and 
inducible nitric oxide synthase (nos2) as M2 and M1 markers respectively (H). Results 
were normalized against ywhaz and gapdh mRNAs. Values are represented as fold 
change over control mice and are means ± SEM of 6 mice per genotype. Statistical 
significance was analyzed by unpaired two-tailed t test. *P <0.05. 
Figure 6.  GRK2 depletion during the course of a HFD can reverse an already 
established obese and insulin resistant phenotype, potentially through its combined 
effects in different tissues. Besides its role as a GPCR kinase, GRK2 inhibits insulin 
signalling and may also control the GPCR-mediated transmodulation of the insulin 
pathway. A reduction in GRK2 abundance after obesity and insulin resistance have been 
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established leads to: (i) an increased adrenergic-dependent lipolytic capacity in eWAT 
that provides BAT with free fatty acids. In turn, BAT displays an enhanced expression 
of oxidative and thermogenic markers, and consequently both tissues may contribute to 
the concerted protection against excessive fat mass accretion; (ii) improved insulin 
signalling in muscle which can underlie the enhanced insulin-induced glucose 
clearance; (iii) increased insulin signalling in liver associated with a decrease in 
triacylglyceride accumulation and inflammation within this tissue. All these processes 
may mediate the protective effects of lowering GRK2 abundance against excessive 
body weight gain and HFD-induced insulin resistance. 
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Tam-induced GRK2 deletion
 Supplementary Figure 1.  Characterization of an obese and insulin-resistant 
phenotype after eight weeks of HFD, before tamoxifen treatment, and 
quantification of tamoxifen-induced GRK2 depletion. (A) Scheme of the 
experimental design: 8 weeks after birth, mice were initiated on a HFD and the 
establishment of insulin resistance and obesity was confirmed 8 weeks later; at this 
stage, mice were injected with tamoxifen, and maintained on HFD for 5 more weeks 
before sacrifice (totalling 13 weeks of HFD). SD, standard diet. Pre-Tam or Post-Tam, 
previous to or after tamoxifen injection respectively. (B) Body weight progression (g) 
during 8 weeks of standard (SD, solid lines) or high fat diet (HFD, dotted lines), before 
tamoxifen treatment in the indicated mouse genotypes.  (C-D) Circulating fasting 
glucose concentrations (C) and intraperitoneal ITTs (D) after 8 weeks of SD (solid 
lines) or HFD (dotted lines), before tamoxifen administration and histogram showing 
the ITT area under the curve (AUC). (E) Lysates of different tissues including heart, 
skeletal muscle, brown adipose tissue (BAT), epidydimal white adipose tissue (eWAT) 
and liver were analyzed by Western Blot with antibodies against GRK2 and GAPDH 
Representative immunoblots and densitometric analysis are shown. Results are 
expressed as percent change from control (Cre-/-GRK2fl/fl) mice. For (B) to (E), results 
are means ± SEM of 6-7 mice per group. Statistical analysis was performed by two-way 
repeated measures ANOVA followed by Bonferroni's post hoc test (B) to (D) and 
unpaired two tailed t-test (E). *P < 0.05, **P < 0.01, ***P<0.005 compared to Cre-/-
GRK2fl/fl mice on a HFD. +P < 0.05, ++P < 0.01, +++P<0.005 compared to Cre+/-
GRK2fl/fl mice on a HFD. ++P < 0.01, +++P<0.005 compared to Cre+/-GRK2fl/fl mice on 
a HFD. 
 
 
 
 
 
 
 
 
 
 
 Supplementary Figure 2. HFD-induced weight gain in control mice compared with 
SD-fed mice.  Body weight progression (g) during 8 weeks of standard (SD, grey lines) 
or high fat (HFD, black lines) diets, before (dotted lines) and after (solid lines) 
tamoxifen treatment in Cre-/-GRK2fl/fl control mice. Results are means ± SEM of 6-7 
mice per group. Statistical analysis was performed by two-way repeated measures 
ANOVA followed by Bonferroni's post hoc test. *P < 0.05; **P < 0.01; ***P<0.005  
 Supplementary Figure 3. CreER expression or translocation to the nucleus does 
not affect body weight gain or insulin-induced phosphorylation of AKT in muscle, 
eWAT, or liver. (A) Body weight evolution (g) before (dotted lines) and after (solid 
lines) tamoxifen treatment in CreER-expressing Cre+/- mice, without floxed GRK2 
alleles, compared to Cre-/-GRK2fl/fl and Cre+/-GRK2fl/fl mice pre- or post-tamoxifen 
treatment. Data are represented as means ± SEM of 5-7 mice per group. Statistical 
analysis was performed by two-way repeated measures ANOVA followed by 
Bonferroni's post hoc test. *P < 0.05, **P < 0.01 compared to Tam-GRK2+/+; #P < 0.05 
compared to Tam-Cre+/-. (Open symbols, dotted lines = Pre-Tam; filled symbols, solid 
lines = Post-Tam; Black = Cre-/-GRK2fl/fl; Red = Cre+/-GRK2fl/fl; Green=Cre+/-). (B) 
Mice that did or did not express Cre recombinase without floxed GRK2 alleles were 
treated or not with insulin for 10 min  and tissue lysates from muscle, eWAT and liver 
were subjected to Western blot and probed with antibodies against GRK2, total  and 
phosphorylated AKT (Ser473), and GAPDH. Representative immunoblots and 
densitometric quantitations are shown. Results are expressed as % of stimulation over 
untreated mice (basal). Data are means ± SEM of 6 animals per genotype, 3 animals per 
treatment. Statistical significance was analyzed by unpaired two tailed t test. *P < 0.05 
  
 Supplementary Figure 4. The abundance of components in or inhibitors of the 
insulin signaling pathway is not changed upon GRK2 loss in muscle or liver. Tissue 
lysates from muscle and liver were subjected to Western blot and probed with 
antibodies against IRS1, IRS2, PI3K isoforms p110 and p85, PTEN, PTP1B, nucleolin, 
and GAPDH. Representative immunoblots and densitometric quantitations are shown. 
Results are expressed as arbitrary units and normalized by either nucleolin or GAPDH. 
Data are means ± SEM of 7-8 mice per group.  Statistical significance was analyzed by 
unpaired two tailed t test or Mann-Whitney test, depending on the normality of the 
distribution of the data. *P < 0.05 
 Supplementary Figure 5. CreER expression or translocation to the nucleus does 
not affect lipid accumulation in the liver. (A) Liver weight in mice expressing (Tam-
Cre+/-) or not (Tam-Cre-/-) Cre recombinase. Statistical significance was analyzed by 
unpaired two tailed t test.  (B) Liver sections from HFD-fed control (Cre-/-) and Tam-
Cre+/- mice were stained with hematoxylin and eosin (scale bar 50 µm). Images are 
representative of 5 mice per genotype. *P <0.05. 
 
 Supplementary Figure 6 Decreased abundance of inflammation markers in the 
liver upon tamoxifen-induced GRK2 loss.  Mice from both genotypes were fed a 
HFD for 8 weeks, injected with tamoxifen and maintained for 5 more weeks in the 
HFD. (A) Quantification of the characteristic hepatic crown-like structures within liver 
sections stained with F4/80 from control and Tam-GRK2-/- mice, indicated by arrows in 
Figure 5E. Results are means ± SEM of 4 mice per genotype.  *P < 0.05; **P < 0.01. 
(b) qPCR was used to measure the hepatic expression of mRNAs for tnfa, mcr1 and 
nos2. Results were normalized against ywhaz and gapdh mRNAs. Values are 
represented as fold change over control mice and are means ± SEM of 6 mice per 
genotype.; *P<0,05. (c) Representative immunoblots and densitometric analysis are 
shown for total and phosphorylated JNK1/2. Values are represented as fold change over 
control mice and are means ± SEM of 3-4 mice per genotype. Statistical significance 
was analyzed by unpaired two-tailed t test or Mann-Whitney test, depending on the 
normality of the distribution of the data. *P <0.05. 
 
 
 
  
Supplementary Table 1. Primers used for real time PCR analysis: 
Emr1 (F4/80) Forward 
Reverse 
5′-AGTACGATGTGGGGCTTTTG-3′ 
5′-CCCCATCTGTACATCCCACT-3′ 
Tnf Forward 
Reverse 
5′-TCTTCTCATTCCTGCTTGTGG-3′ 
5′-GGTCTGGGCCATAGAACTGA-3′ 
Mrc1(CD206) Forward 
Reverse 
 5′-CCACAGCATTGAGGAGTTTG-3′ 
5′-ACAGCTCATCATTTGGCTCA-3′ 
Nos2 (iNOS) Forward 
Reverse 
5′-TGAACTTGAGCGAGGAGCA-3′ 
5′-TTCATGATAACGTTTCTGGCTCT-3′ 
Gapdh Forward 
Reverse 
5′-CTGCACCACCAACTGCTTAGC-3′ 
5′-GGTCATGAGCCCTTCCACAAT-3′ 
Ywhaz Forward 
Reverse 
5′- TTACTTGGCCGAGGTTGCT-3 
5′-TGCTGTGACTGGTCCACAAT-3′ 
Cpt1a Forward 
Reverse 
5′- GACTCCGCTCGCTCATTC -3′ 
5′-TCTGCCATCTTGAGTGGTGA-3′ 
Cpt1b Forward 
Reverse 
5′-GAGTGACTGGTGGGAAGAATATG -3′ 
5′-GCTGCTTGCACATTTGTGTT-3′ 
pparg Forward 
Reverse 
5′-TGCTGTTATGGGTGAAACTCTG -3′ 
5′-TCTGTGTCAACCATGGTAATTTCT-3′ 
fasn Forward 
Reverse 
5′-GCTGCTGTTGGAAGTCAGC -3′ 
5′-AGTGTTCGTTCCTCGGAGTG-3′ 
dio2 Forward 
Reverse 
5′-AGCTTCCTCCTAGATGCCTACA -3′ 
5′-CCGAGGCATAATTGTTACCTG-3′ 
Ucp1 Forward 
Reverse 
5′-GGCCTCTACGACTCAGTCCA -3′ 
5′-TAAGCCGGCTGAGATCTTGT-3′ 
ppargc1 Forward 
Reverse 
5′-CCCTTCTTTGCCATTGAATC -3′ 
5′-AATGTTAGGAAAGTTTAGCATCTGG-3′ 
lipe Forward 
Reverse 
5′- AGCGCTGGAGGAGTG-3′ 
5′-CCGCTCTCCAGTTGAACC-3′ 
	  
